NSGO_org

The Nordic Society of Gynaecological Oncology & Cinical Trial Unit

[NSGO_org @nsgo_org]

⚡Dr. Mirza and RUBY Investigator colleagues published on the landing page of NEJM

Title: 𝑫𝒐𝒔𝒕𝒂𝒓𝒍𝒊𝒎𝒂𝒃 𝒇𝒐𝒓 𝑷𝒓𝒊𝒎𝒂𝒓𝒚 𝑨𝒅𝒗𝒂𝒏𝒄𝒆𝒅 𝒐𝒓 𝑹𝒆𝒄𝒖𝒓𝒓𝒆𝒏𝒕 𝑬𝒏𝒅𝒐𝒎𝒆𝒕𝒓𝒊𝒂𝒍 𝑪𝒂𝒏𝒄𝒆𝒓

 📢https://t.co/ao4zea241Q📣

#NEJM #RUBY #NSGO #Mirza

[NSGO_org @nsgo_org]

🌟 Dr. Kristina Lindemann presents TIP for #PEACE 🌟 Investigating #palliation in #gynecologic #oncology, this research aims to improve patient-centered care for women battling gynecologic cancers. #ASCO2023 #GynecologicOncology
#NSGOCTUPEACE

https://t.co/l0pO8pm4nU

[NSGO_org @nsgo_org]

🔬🌟 #ASCO2023 Highlights: NSGO-CTU shines bright! Dr. Mansoor Raza #Mirza and Dr. Kristina Lindemann present groundbreaking work in gynecologic oncology. #ResearchBreakthroughs #GynecologicOncology #NSGO

See the TIP on https://t.co/qmX2qJOdW6: https://t.co/VSR9ZCO5Dy

[NSGO_org @nsgo_org]

@ArturasDobilas @OncoAlert Hi, I think you tagged the wrong account, but thanks. We're https://t.co/zRdXtBVK5U -

[NSGO_org @nsgo_org]

Exciting news! Dr. Mirza presented groundbreaking research on PROs in endometrial cancer patients at #ASCO2023. The study highlights the benefits of dostarlimab plus CP, improving quality of life. Congratulations to the research team! #endometrialcancer #oncology #NSGO #Mirza

[NSGO_org @nsgo_org]

Join The #NSGO Annual Meeting 2023 in Reykjavik June 14 - 16!
The event features presentations from renowned speakers on various topics, including the latest updates in #clinicaltrials, #surgery, and #radiationtherapy

#NSGO2023 #GynecologicalOncology #Reykjavik #ClinicalTrials

[NSGO_org @nsgo_org]

Dr. Mirza shared his knowledge on the latest advancements in #EndometrialCancer at The 12th International #Charité Mayo Conference 2023 in Berlin last week while connecting with friends, colleagues, and associates.

#CharitéMayoConference #CancerResearch #DrMirza #NSGOCTU #NOGGO

[NSGO_org @nsgo_org]

Prospective evaluation of the tolerability and efficacy of #niraparib dosing based on baseline body weight and platelet count: 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 #𝐏𝐑𝐈𝐌𝐀/#𝐄𝐍�#𝐄𝐍𝐆𝐎𝐓-𝐎𝐕26/#𝐆𝐎𝐆-3012 #𝐭𝐫𝐢𝐚𝐥 https://t.co/BgWj1isP5L

[NSGO_org @nsgo_org]

We had the opportunity to welcome the Nordic team from #AstraZeneca at our office in Copenhagen to exchange insights, ideas, & updates on ongoing trials. Thank you CTU 𝐏𝐫𝐨𝐣𝐞𝐜𝐭 𝐌𝐚𝐧𝐚𝐠𝐞𝐫𝐬📷 #Rigshospitalet #GynaecologicalOncology #ClinicalTrials #HealthcareInnovation

[NSGO_org @nsgo_org]

@NicoloBizzarri @DrZoiaRazumova @AStrojnaMD @Joanna86992517 @BjerreTrent @brinklaursen @HsuMd @esragbilir

[NSGO_org @nsgo_org]

Interview with @MirzaCPH on the management of #ovariancancer is already available online! Check it out! 📺

@ESGO_society @ENYGO_official #NSGO

@IJGConline @IJGCfellows @pedroramirezMD @Joanna86992517

[European Network of Young Gynae Oncologists @ENYGO_official]

In this interview Prof. Mansoor Raza Mirza and @Joanna86992517 discuss about major achievements in the management of #ovariancancer https://t.co/d1jejDvz4c
Full-text with all interviews: https://t.co/SoQuhM0iGe
Video recording and edit by @esragbilir
@ESGO_society @IJGConline

[NSGO_org @nsgo_org]

Join us in #Iceland!🇮🇸

#NSGO ANNUAL MEETING 2023

-> Registration Is Open Until June 8th, 2023

@DrLB @MirzaCPH @agz_eriksson @DrZoiaRazumova @BjerreTrent

@ESGO_society @ENYGO_official

#NSGO2023

https://t.co/1omTYUDbwm

[NSGO_org @nsgo_org]

𝐄𝐍𝐆𝐎𝐓, 𝐍𝐒𝐆𝐎-𝐂𝐓𝐔 & 𝐆𝐎𝐆 𝐩𝐫𝐨𝐮𝐝𝐥𝐲 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐭𝐡𝐞 𝐠𝐫𝐨𝐮𝐧𝐝-𝐛𝐫𝐞𝐚𝐤𝐢𝐧𝐠 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐨𝐟 𝐄𝐍𝐆𝐎𝐓-𝐄𝐍6-𝐍𝐒𝐆𝐎/𝐆𝐎𝐆-3031/𝐑𝐔𝐁𝐘 𝐭𝐫𝐢𝐚𝐥.
https://t.co/d68OfTbAkx

#Endometrial #Cancer #RUBY #NSGO #ENGOT #Dostarlimab #ESMO #SGO

[NSGO_org @nsgo_org]

We're very excited about the data that our Medical Director, Mansoor Raza Mirza, will present at the #ESMOVirtualPlenary Monday March 27th about the #RUBYTrial

#NSGOCTU #NSGO #ENGOT #ESMO #EndometrialCancer

[ESMO - Eur. Oncology @myESMO]

#ESMOVirtualPlenary: Do patients with advanced #endometrialcancer benefit from the addition of dostarlimab to first-line platinum-based #chemotherapy?
⏰ Join us for the first session - 27 March at 18:30 CEST
https://t.co/Tyan0NcF9l

#MedOnc #MedEd #MedTwitter #GynCSM @AACR

[ESMO - Eur. Oncology @myESMO]

#ESMOVirtualPlenary: Do patients with advanced #endometrialcancer benefit from the addition of dostarlimab to first-line platinum-based #chemotherapy?
⏰ Join us for the first session - 27 March at 18:30 CEST
https://t.co/Tyan0NcF9l

#MedOnc #MedEd #MedTwitter #GynCSM @AACR

[NSGO_org @nsgo_org]

#NSGO-CTU will collaborate with #Kancera in our upcoming ovarian cancer study -a combined phase Ib/IIa!
https://t.co/U9ngNyKOjq

[NSGO_org @nsgo_org]

Happy Holidays from NSGO-CTU 🎄

[NSGO_org @nsgo_org]

An interim analysis of the key secondary endpoint showed a median OS of 46.3 months for patients receiving #niraparib vs 43.4 months for patients receiving placebo(HR 0.82, 95% CI 0.56-1.20) in the ITT population - #MansoorRazaMirza, #Rigshospitalet. https://t.co/EmFCjLdlE7 #NSGO

[NSGO_org @nsgo_org]

#ESMO Virtual Plenary - Dr. Mansoor Raza Mirza will give a live talk on results from the NORA trial on Dec. 15th at 18.30 – 19.30 CET.

https://t.co/g1DX9aNZ3u

#NORAtrial #ESMO #Gynaeological #Oncology #GSK #NSGO

[NSGO_org @nsgo_org]

#NSGO is dedicated to the development of new clinical trials and fostering research studies.
Visit https://t.co/X0VznX5ZtJ to find the guidelines & Concept Development Form, which is used for submitting new study proposals to NSGO.
#clinicaltrials #research #development #study